News

Custom R&D Collaboration for Cardiovascular Pharmaceutical Intermediates

A well-known pharmaceutical company urgently needed high-purity cardiovascular pharmaceutical intermediates to advance the development of a new antihypertensive drug. Leveraging its in-house R&D team, the company conducted customized technical research tailored to the client's needs, completing process optimization and pilot production of the target intermediate within three months, achieving a purity of 99.8%. Subsequent large-scale production support helped the pharmaceutical company smoothly advance its new drug clinical trials. This led to the establishment of a long-term strategic partnership with an annual value exceeding 20 million yuan.

Get in touch